Mereo BioPharma Group plc - Sponsored ADR
MREO Healthcare Biotechnology
Mereo BioPharma Group plc - Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $500,000.00, down 95.0% from fiscal 2023. In the quarter to June 2026, EPS grew 52.3% and free cash flow grew 21.0%, each against the same quarter a year earlier.
Follow MREO
Mereo BioPharma Group plc - Sponsored ADR (MREO) Piotroski F-score
Mereo BioPharma Group plc - Sponsored ADR's Piotroski F-score for fiscal 2025 cannot be worked out: no comparable prior fiscal year (a missing year or a changed year end).
Piotroski F-score, annual
Annual newest first
| Period | Piotroski F-score | Change (points) |
|---|
How fiscal 2025’s score is made up
| Test | This year | Year before | Result | Points |
|---|---|---|---|---|
| Positive return on assets | — | — | n/a | — |
| Positive operating cash flow | (30.97m) | — | Fail | 0 |
| Rising return on assets | — | — | n/a | — |
| Cash flow above net income | 10.91m | — | Pass | 1 |
| Falling long-term leverage | — | — | n/a | — |
| Rising current ratio | 10.46 | — | n/a | — |
| No new shares issued | 159,424,000 | — | n/a | — |
| Rising gross margin | 73.40% | — | n/a | — |
| Rising asset turnover | — | — | n/a | — |
| Piotroski F-score | n/a — no comparable prior fiscal year (a missing year or a changed year end) | — | ||
How the Piotroski F-score works
One point for each of nine tests, this fiscal year against the one before: positive return on assets, positive operating cash flow, rising return on assets, cash flow above net income, falling long-term leverage, a rising current ratio, no new shares issued, a rising gross margin and rising asset turnover. The ratios are the ones on this site, so each can be checked.
Joseph Piotroski (2000) called 8–9 high and 0–1 low; reading it in three bands is the common convention:
| 7–9 | Strong — most fundamentals improved |
|---|---|
| 4–6 | Mixed |
| 0–3 | Weak — most fundamentals deteriorated |
Where this differs from the paper: return on assets is on average rather than beginning-of-year assets, and weighted basic shares stand in for shares issued. The score is shown only when all nine tests can be worked out, which takes three fiscal years; banks and insurers, which report no current assets or gross profit, have none.
Piotroski F-score against peers
| Company | Piotroski F-score |
|---|---|
| ELTX Elicio Therapeutics, Inc. compare | 6 |
| HYPD Hyperion DeFi, Inc. compare | 5 |
| ACET Adicet Bio, Inc. compare | 4 |
| CRBU Caribou Biosciences, Inc. compare | 3 |
| HOWL Werewolf Therapeutics, Inc. compare | 3 |
| KLRS Kalaris Therapeutics Inc. compare | — |
| LONA LeonaBio, Inc. compare | — |
| MREO Mereo BioPharma Group plc - Sponsored ADR | — |
| INKT MiNK Therapeutics, Inc. compare | — |
What Piotroski F-score is
The Piotroski F-Score tells an investor how many signs of improving profitability, funding and efficiency a company shows against a year earlier.
One point for each of nine tests against a year earlier: positive return on assets, positive operating cash flow, rising return on assets, cash flow above net income, falling long-term leverage, rising current ratio, no new shares issued, rising gross margin, and rising asset turnover